Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe

Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million i…

Alfasigma Expands Presence in Europe with Acquisition of Nordic Pharma, Maker of Lacrifill Canalicular Gel

Key Takeaways Alfasigma has agreed to acquire 100% of Nordic Pharma and its subsidiaries from Sever Life Sciences The transaction includes Nordic Pharma’s ophthalmology portfolio and expands Alfasigma’s commercial presence across Europe, Canada, and Japan Nordic Pharma is the maker of the Lacrifill Canalicular Gel for dry eye disease Alfasigma has entered into a share purchase agreement with Sever Life Sciences B.V. to acquire 100% of Nordic G…

HSF Kramer advises SEVER Life Sciences B.V. on the sale of Nordic Group B.V.

Herbert Smith Freehills Kramer has advised SEVER Life Sciences B.V. on the sale of Nordic Group...

Alfasigma signs agreement to acquire Nordic Group

Alfasigma is to buy Nordic Group, which aims to strengthen its speciality care business and expand its reach in Europe, Canada, and Japan.The post Alfasigma signs agreement to acquire Nordic Group appeared first on Hospital Management.

SEVER Life Sciences B.V. Signs Agreement to Sell Nordic Group B.V. to Alfasigma S.p.A.

Just another WordPress site